Suchergebnisse - "Laharie, David"

PubPharm (20)

1

Histological healing induced by tofacitinib in ulcerative colitis : A multicentre study

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2024

von Vieujean, S. | Laharie, D. | Buisson, A. | +8

2

Review article : Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies

enthalten in: United European gastroenterology journal | 2023

von Calméjane, L. | Laharie, D. | Kirchgesner, J. | +1

3

Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease : A Retrospective Study From 2 Referral Centers

enthalten in: Inflammatory bowel diseases | 2023

von Rivière, P. | Kanters, C. | Pellet, G. | +10

4

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE) : a multicentre, open-label, randomised controlled trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Louis, E. | Resche-Rigon, M. | Laharie, D. | +49

CommentIn: Lancet Gastroenterol Hepatol. 2023 Mar;8(3):200-201. - PMID 36640793

5

Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease : A GETAID multicentre cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2023

von Fumery, M. | Defrance, A. | Roblin, X. | +22

CommentIn: Aliment Pharmacol Ther. 2023 Apr;57(8):909-910. - PMID 36952268

6

Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease : the COMBIO study

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Guillo, L. | Flachaire, B. | Avouac, J. | +65

7

Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT) : a randomised, placebo-controlled, double-blind, phase 3 trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Sandborn, W. | Panés, J. | Danese, S. | +14

8

Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis : a GETAID multicentre cohort study

enthalten in: Scandinavian journal of gastroenterology | 2022

von Meyer, A. | Fumery, M. | Peyrin-Biroulet, L. | +22

9

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease : a multicentre retrospective study

enthalten in: BMC gastroenterology | 2022

von Rayer, C. | Nachury, M. | Bourreille, A. | +10

ErratumIn: BMC Gastroenterol. 2023 Feb 2;23(1):31. - PMID 36732693

10

How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients

enthalten in: Scandinavian journal of gastroenterology | 2022

von Brunet-Houdard, S. | Monmousseau, F. | Berthon, G. | +12